These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36059463)

  • 1. Immunological signature of patients with thymic epithelial tumors and Good syndrome.
    Malfitano AM; D'Esposito V; De Placido P; Tortora M; Ottaviano M; Pietroluongo E; Morra R; Mucci B; Napolitano F; Montella L; Giuliano M; De Placido S; Terracciano D; Palmieri G; Formisano P
    Front Immunol; 2022; 13():908453. PubMed ID: 36059463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study.
    Pietroluongo E; Peddio A; De Placido P; Tortora M; Ottaviano M; Gelzo M; Cernera G; Foggia M; Buonomo AR; Pinchera B; Zappulo E; Mercinelli S; Cattaneo L; Sardanelli A; Viceconte G; Scotto R; Schiano Moriello N; Servetto A; De Angelis C; Arpino G; Palmieri G; De Placido S; Bianco R; Castaldo G; Gentile I; Giuliano M
    BMC Cancer; 2024 Jun; 24(1):748. PubMed ID: 38898390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic potential of CD4 and CD8 single-positive T cells in thymic epithelial tumors.
    Yamamoto Y; Iwahori K; Funaki S; Matsumoto M; Hirata M; Yoshida T; Kanzaki R; Kanou T; Ose N; Minami M; Sato E; Kumanogoh A; Shintani Y; Okumura M; Wada H
    Sci Rep; 2020 Mar; 10(1):4064. PubMed ID: 32132638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe FOXP3+ and naïve T lymphopenia in a non-IPEX form of autoimmune enteropathy combined with an immunodeficiency.
    Zuber J; Viguier M; Lemaitre F; Senée V; Patey N; Elain G; Geissmann F; Fakhouri F; Ferradini L; Julier C; Bandeira A
    Gastroenterology; 2007 May; 132(5):1694-704. PubMed ID: 17484867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment serum neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios: Two tumor-related systemic inflammatory markers in patients with thymic epithelial tumors.
    Wang L; Ruan M; Yan H; Lei B; Sun X; Chang C; Liu L; Xie W
    Cytokine; 2020 Sep; 133():155149. PubMed ID: 32512341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation.
    Bellissimo T; Ganci F; Gallo E; Sacconi A; Tito C; De Angelis L; Pulito C; Masciarelli S; Diso D; Anile M; Petrozza V; Giangaspero F; Pescarmona E; Facciolo F; Venuta F; Marino M; Blandino G; Fazi F
    Mol Cancer; 2017 May; 16(1):88. PubMed ID: 28486946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell lymphopenia and hypogammaglobulinemia in thymoma patients.
    Montella L; Masci AM; Merkabaoui G; Perna F; Vitiello L; Racioppi L; Palmieri G
    Ann Hematol; 2003 Jun; 82(6):343-7. PubMed ID: 12715206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe T- and B-cell immune deficiency associated with malignant thymoma.
    Yel L; Liao O; Lin F; Gupta S
    Ann Allergy Asthma Immunol; 2003 Nov; 91(5):501-5. PubMed ID: 14692437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmune Disease in Patients With Advanced Thymic Epithelial Tumors.
    Singhal S; Hellyer J; Ouseph MM; Wakelee HA; Padda SK
    JTO Clin Res Rep; 2022 May; 3(5):100323. PubMed ID: 35601925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymic epithelial tumor complicated by immunological abnormalities: results from a single-center retrospective study in China.
    Shi TY; Wen XH; Shi XH; Lu YW
    J Thorac Dis; 2019 Apr; 11(4):1580-1588. PubMed ID: 31179102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting pathological subtypes and stages of thymic epithelial tumors using DWI: value of combining ADC and texture parameters.
    Li B; Xin YK; Xiao G; Li GF; Duan SJ; Han Y; Feng XL; Yan WQ; Rong WC; Wang SM; Hu YC; Cui GB
    Eur Radiol; 2019 Oct; 29(10):5330-5340. PubMed ID: 30877464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of PD-L1, transforming growth factor-β expression and tumor-infiltrating CD8
    Duan J; Liu X; Chen H; Sun Y; Liu Y; Bai H; Wang J
    Thorac Cancer; 2018 Nov; 9(11):1341-1353. PubMed ID: 30168897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine profiles contribute to understanding the pathogenic difference between Good syndrome and oral lichen planus: two case reports and literature review.
    Maehara T; Moriyama M; Kawano S; Hayashida JN; Furukawa S; Ohta M; Tanaka A; Yamauchi M; Ohyama Y; Kiyoshima T; Nakamura S
    Medicine (Baltimore); 2015 Apr; 94(14):e704. PubMed ID: 25860215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptome profiling of human thymic CD4+ and CD8+ T cells compared to primary peripheral T cells.
    Helgeland H; Gabrielsen I; Akselsen H; Sundaram AYM; Flåm ST; Lie BA
    BMC Genomics; 2020 May; 21(1):350. PubMed ID: 32393182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 and Cancer: Discovery of Difference in Clinical Immune Indexes.
    Zeng X; Jiang X; Yang L; Pan Y; Li Y
    J Immunol Res; 2021; 2021():8669098. PubMed ID: 34712741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-mediated diseases and immunodeficiencies associated with thymic epithelial neoplasms.
    Khawaja MR; Nelson RP; Miller N; Badve SS; Loehrer E; Czader M; Perkins SM; Kesler K; Loehrer PJ
    J Clin Immunol; 2012 Jun; 32(3):430-7. PubMed ID: 22228568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immune landscape of human thymic epithelial tumors.
    Xin Z; Lin M; Hao Z; Chen D; Chen Y; Chen X; Xu X; Li J; Wu D; Chai Y; Wu P
    Nat Commun; 2022 Sep; 13(1):5463. PubMed ID: 36115836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant Alteration of Circulating Lymphocyte Subsets in Small Cell Lung Cancer Patients Treated with Radiotherapy.
    Li H; Yu H; Lan S; Zhao D; Liu Y; Cheng Y
    Technol Cancer Res Treat; 2021; 20():15330338211039948. PubMed ID: 34851203
    [No Abstract]   [Full Text] [Related]  

  • 19. Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME).
    Imbimbo M; Ottaviano M; Vitali M; Fabbri A; Leuzzi G; Fiore M; Franceschini D; Pasello G; Perrino M; Schiavon M; Pruneri G; Dei Tos AP; Sangalli C; Garassino MC; Berardi R; Alessi A; Calareso G; Petrini I; Scorsetti M; Scotti V; Rosso L; Rea F; Pastorino U; Casali PG; Ramella S; Ricardi U; Abate-Daga L; Torri V; Trama A; Palmieri G; Marino M; Zucali PA;
    Cancer Treat Rev; 2018 Dec; 71():76-87. PubMed ID: 30366202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
    Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD
    PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.